GlassScriptPhysician profile
Audrey Nicholson
NPI 1922556208
$6,072.23
in general payments reported to CMS, 2019-2025
18 companies · $2,699 in 2025
The $2,699 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $401 · 2023: $1,851 · 2024: $855 · 2025: $2,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,268 · Travel and Lodging: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.93 |
| Travel and Lodging | $2,137.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,647.61 | 2023-2024 | |
| Medtronic, INC. | $1,616.83 | 2025 | Linq II |
| Abbott Laboratories | $1,393.36 | 2021-2025 | Aveir, Jot Dx, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $429.38 | 2022-2025 | Lifevest |
| Heartflow, INC. | $321.28 | 2025 | |
| Biosense Webster, INC. | $182.18 | 2025 | Carto 3 |
| Edwards Lifesciences Corporation | $136.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $66.38 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $64.57 | 2021-2023 | Xarelto |
| Abiomed | $39.13 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $33.05 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.88 | 2021-2022 | |
| Amgen INC. | $25.04 | 2022-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $24.46 | 2024 | Wainua |
| Boston Scientific Corporation | $17.29 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $16.61 | 2025 | Vitalpatch Rtm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.34 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.